The health technology assessment of companion diagnostics:Experience of nice

Clinical Cancer Research

Volumn 20, Issue 6, 2014, Pages 1469-1476

  Byron, Sarah K ^a   Crabb, Nick ^a   George, Elisabeth ^a   Marlow, Mirella ^a   Newland, Adrian ^a  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL RESEARCH; COMPANION DIAGNOSTIC TEST; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REIMBURSEMENT; RESOURCE MANAGEMENT; SENSITIVITY AND SPECIFICITY; BIOMEDICAL TECHNOLOGY ASSESSMENT; ECONOMICS; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; PROCEDURES; PUBLIC HEALTH; STANDARDS; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; NATIONAL HEALTH PROGRAMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84896535710     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1955     Document Type: Article

References (18)

1. Fugel HJ, Nuijten M, Postma M. Stratified Medicine and reimbursement issues. Front Pharmacol 2012 3:181.
2. Senderowicz AM, Pfaff O. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics. Clin Cancer Res 2014; 20:1445-52.
3. Diagnostics Assessment Report: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer, National Institute for Health and care Excellence. [updated April 2013; cited 2013 Oct 6] Available from: http://guidance.nice.org. uk/DT/11/DAR/pdf/English.
4. FDA Guidance for Industry and Food and Drug Administration Staff -In Vitro Companion Diagnostic Devices, Draft Guidance. [updated July 2011; cited 2013 Oct 6] Available from: http://www.fda.gov/medicaldevices/ deviceregulationandguidance/guidancedocuments/ucm262292.htm.
5. FDA Guidance for IVD regulatory assistance: CLIA waivers. [cited 2013 Oct 6]. Available from: http://www.fda.gov/medicaldevices/ deviceregulationandguidance/ivdregulatoryassistance/ucm124202.htm.
6. NHS Constitution. [cited 2013 Oct 6]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/ 170656/NHS-Constitution.pdf.
7. Guide to the methods of technology appraisal, National Institute for Health and Care Excellence. [updated April 2013; cited 2013 Oct 6]. Available from: http://publications.nice.org.uk/guide-to-the-methodsof-technology- Appraisal-2013-pmg9/the-reference-case.
8. Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res 2014;20:1428-44.
9. Diagnostics guidance DG9: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer, National Institute for Health and Care Excellence. [updated August 2013; cited 2013 Oct 6]. Available from: http://www.nice.org.uk/ dg9.
10. Technology appraisal guidance TA192 Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, National Institute for Health and Care Excellence. [updated July 2010; cited 2013 Oct 6]. Available from: http://www.nice.org. uk/ta192.
11. Technology appraisal guidance TA258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer, National Institute for Health and Care Excellence. [updated June 2012; cited 2013 Oct 6]. Available from: http://guidance.nice.org.uk/TA258.
12. Medical technologies evaluation programme: process guide, National Institute for Health and Care Excellence. [updated April 2011; cited 2013 Oct 6]. Available from: http://www.nice.org.uk/aboutnice/whatwedo/ aboutmedicaltechnologies/MTEPProcessGuideAndMethodsGuide. jsp?domedia=1&mid= 67EFA8F7-19B9-E0B5-D4A02970AC0FAAF2
13. Final Scope: Epidermal growth factor receptor tyrosine kinase (EGFRTK) mutation testing in adults with locally advanced or metastatic nonsmall-cell lung cancer, National Institute for Health and care Excellence. [updated August 2012; cited 2013 Oct 6]. Available from: http://guidance.nice.org.uk/DT/11/ Scope/pdf/English.
14. Diagnostics Assessment Programme manual, National Institute for Health and Care Excellence. [updated February 2012; cited 2013 Oct 6]. Available from: http://www.nice.org.uk/aboutnice/whatwedo/aboutdiagnosticsassessment/ DiagnosticsAssessment-ProgrammeManual.jsp?domedia =1&mid =8A32125A-19B9-E0B5-D46C9C0F25A558DD
15. Approval of Herceptin. [cited 2013 Oct 6]. Available from: http://www.gene.com/media/product-information/herceptin-developmenttimeline.
16. Review of Health Technology Assessment in Australia. Australian government. Department of Health and Ageing. [updated Dec 2009; cited 2013 Oct 6]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/ Content/AF68234CE9EB8A78CA257BF00018CBEB/File/hta-review-report.pdf.
17. Mansfield EA.FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res 2014;20:1453-7.
18. Australiangovernment.Department ofHealth andAgeing. [updatedDec 2009; cited 2013Oct 6] Availablefrom: http://www.health.gov.au/internet/hta/ publishing.nsf/Content/170AAB0885294EAFCA25774200820890/File/htaap-info-pack. pdf.